Steve Pakola Sells 15,309 Shares of REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 15,309 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $11.02, for a total transaction of $168,705.18. Following the completion of the sale, the insider owned 232,617 shares in the company, valued at approximately $2,563,439.34. This trade represents a 6.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Steve Pakola also recently made the following trade(s):

• On Tuesday, March 10th, Steve Pakola sold 5,124 shares of REGENXBIO stock. The shares were sold at an average price of $10.35, for a total transaction of $53,033.40.

REGENXBIO Stock Performance

Shares of REGENXBIO stock traded down $0.20 during trading on Wednesday, reaching $10.04. The company had a trading volume of 1,800,523 shares, compared to its average volume of 910,122. The company has a market cap of $518.26 million, a price-to-earnings ratio of -2.67 and a beta of 1.12. The firm’s fifty day moving average is $8.96 and its 200-day moving average is $11.10. REGENXBIO Inc. has a fifty-two week low of $7.35 and a fifty-two week high of $16.19.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.29). The company had revenue of $30.34 million during the quarter, compared to analyst estimates of $45.48 million. REGENXBIO had a negative net margin of 113.75% and a negative return on equity of 103.12%. On average, research analysts anticipate that REGENXBIO Inc. will post -2.88 EPS for the current fiscal year.

Institutional Trading of REGENXBIO

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. raised its holdings in shares of REGENXBIO by 4.8% during the third quarter. JPMorgan Chase & Co. now owns 4,037,248 shares of the biotechnology company’s stock worth $38,959,000 after purchasing an additional 185,223 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of REGENXBIO by 64.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,160,380 shares of the biotechnology company’s stock worth $16,709,000 after acquiring an additional 454,977 shares during the period. Invenomic Capital Management LP acquired a new stake in shares of REGENXBIO in the 3rd quarter worth about $4,120,000. Integral Health Asset Management LLC increased its holdings in shares of REGENXBIO by 57.1% in the 3rd quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $10,615,000 after acquiring an additional 400,000 shares during the period. Finally, ACT Capital Management LLC acquired a new stake in shares of REGENXBIO in the 4th quarter worth about $1,188,000. 88.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RGNX has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of REGENXBIO from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. UBS Group reissued an “overweight” rating and set a $18.00 target price on shares of REGENXBIO in a report on Tuesday, February 10th. Robert W. Baird set a $27.00 target price on shares of REGENXBIO in a report on Tuesday, February 10th. The Goldman Sachs Group dropped their target price on shares of REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Tuesday, February 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a report on Thursday, January 22nd. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $27.50.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.